(Q34733976)

4 August 2017

0 references

1 reference

title

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials (English)

1 reference

4 August 2017

0 references

0 references

S Leucht

1

1 reference

4 August 2017

D Arbter

2

1 reference

4 August 2017

R R Engel

3

1 reference

4 August 2017

J M Davis

5

1 reference

4 August 2017

W Kissling

4

1 reference

4 August 2017

language of work or name

English

0 references

publication date

8 January 2008

1 reference

4 August 2017

1 reference

4 August 2017

14

1 reference

4 August 2017

4

1 reference

4 August 2017

429-447

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.mp.4002136

4 August 2017

0 references

cites work

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Efficacy of antidepressants in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Social adversity, the serotonin transporter (5-HTTLPR) polymorphism and major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Neuroleptic withdrawal in schizophrenic patients. A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

'Akinetic Depression' in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Selection Bias in Clinical Trials With Antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Benign breast disease--the risks of communicating risk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Treatment of negative symptoms in schizophrenia with amisulpride

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Improvement of some schizophrenic deficit symptoms with low doses of amisulpride

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Linking the PANSS, BPRS, and CGI: clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

EMPLOYMENT CHARACTERISTICS OF DISCHARGED SCHIZOPHRENICS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002136

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4002136

1 reference

4 August 2017

1 reference